Company Overview of Calithera Biosciences, Inc.
Calithera Biosciences, Inc., a biopharmaceutical company, engages in the discovery and development of small molecule therapeutics for the treatment of cancer and other proliferative diseases. The company focuses on developing an inhibitor for an enzyme in one of the primary metabolic pathways that is frequently altered in cancer cells. It develops small molecules that directly activate caspases and proteases that are responsible for initiating programmed cell death or apoptosis in cancer cells. Calithera Biosciences, Inc. was formerly known as Protein Activation Therapeutics, Inc. The company was founded in 2010 and is based in South San Francisco, California.
343 Oyster Point Boulevard
South San Francisco, CA 94080
Founded in 2010
Key Executives for Calithera Biosciences, Inc.
Senior Director of Human Resources and Operations
Senior Vice President of Research
Senior Vice President of Drug Discovery
Senior Vice President of Development
Compensation as of Fiscal Year 2013.
Calithera Biosciences, Inc. Key Developments
Calithera Biosciences Initiates Three Phase 1 Trials with First-in-Class Glutaminase Inhibitor CB-839 in Patients with Advanced Solid and Hematological Cancers
Feb 24 14
Calithera Biosciences, Inc. announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and survival. Two additional Phase 1 studies, one in patients with advanced multiple myeloma and non-Hodgkin's lymphoma and another in patients with acute leukemias, are being conducted in parallel. All three Phase 1 clinical trials are single-arm, open-label dose escalation studies that allow for expansion in specific tumor types once the maximum tolerated dose is reached. The primary objectives of each of these studies are to determine the safety and tolerability of CB-839 and to establish a dose for Phase 2 studies. Secondary endpoints of the Phase 1 clinical studies include pharmacokinetics, pharmacodynamics and evidence of anti-tumor response. Predictive biomarkers are also being evaluated. The trials are being conducted at clinical sites in the United States. While most normal cells rely primarily on glucose as a fuel, many tumor cells rely on the amino acid glutamine to meet the demands of rapid growth under conditions that limit nutrient and oxygen availability. Glutaminase, the first enzyme in the glutamine metabolism pathway, controls the conversion of glutamine to glutamate. In glutamine-requiring cancer cells, inhibition of glutaminase with CB-839 results in depletion of intracellular pools of TCA cycle intermediates, glutathione, and amino acids. This leads to inhibition of cell growth and often leads to induction of apoptosis. In preclinical studies, CB-839 is effective against a significant fraction of tumor cells from a variety of solid and hematologic tumor cell types, including triple-negative breast cancer, non-small cell lung cancer, renal cell carcinoma, mesothelioma, multiple myeloma, diffuse large B-cell lymphoma and acute leukemias. CB-839 suppresses tumor growth in preclinical animal models, but is well tolerated on a continuous daily dosing regimen, highlighting the tumor-specific impact of glutaminase inhibition. Calithera presented some of these preclinical results in December 2013 at the 55(th) American Society of Hematology (ASH) Annual Meeting and at the 2013 San Antonio Breast Cancer Symposium.
Calithera Biosciences, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-12-2014 09:30 AM
Jan 8 14
Calithera Biosciences, Inc. Presents at Boston Biotech Conferences LLC's East/West CEO Conference, Jan-12-2014 09:30 AM. Venue: Four Seasons Hotel, San Francisco, California, United States. Speakers: Susan M. Molineaux, Co-Founder, Chief Executive Officer, President and Director.
Calithera Biosciences Presents Data for CB-839 in Triple-Negative Breast Cancer Models at the 2013 San Antonio Breast Cancer Symposium
Dec 12 13
Calithera Biosciences announced the presentation of preclinical data for its lead anti-cancer therapeutic candidate, CB-839, at the 2013 San Antonio Breast Cancer Symposium. CB-839 is a potent, selective, orally available glutaminase inhibitor that interferes with tumor metabolism and blocks cancer cell growth and survival. The anti-tumor activity of CB-839 was evaluated in a panel of breast tumor cell lines that included both triple-negative breast cancer and hormone receptor-positive subtypes. Triple-negative breast cancers displayed higher sensitivity to CB-839 treatment, and this sensitivity was correlated with high glutaminase expression relative to tumor cells that were estrogen receptor positive. In vitro treatment with CB-839 reduced cell viability and induced apoptosis in the majority of triple negative breast cancer cell lines. CB-839 treatment also resulted in significant anti-tumor activity in two triple-negative breast cancer xenograft models: as a single agent in a patient-derived tumor with a metabolite and expression profile suggestive of high glutamine utilization, and in a second cell line model in which CB-839 demonstrated robust anti-cancer activity both as a single agent and in combination with paclitaxel. To verify biomarker indicators for CB-839 sensitivity, Calithera researchers studied the Cancer Genome Atlas mRNA expression dataset (n=756) of primary human breast cancers and confirmed a pattern of significantly increased markers of glutaminase in triple-negative breast cancers relative to hormone-receptor driven tumors. Similar observations were made at the metabolite level in 262 primary breast tumors, suggesting that biomarkers of glutamine utilization and high glutaminase expression may be useful in identifying patients most likely to benefit from CB-839.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 7, 2013